Femasys Advances FemBloc Toward U.S. Approval With FDA-Approved Modular PMA Pathway

Femasys (FEMY) received FDA approval for a modular PMA submission approach for FemBloc, its investigational non-surgical permanent birth control technology. The pathway allows key components of the application to be reviewed ahead of final clinical data, advancing FemBloc toward potential U.